



Published in final edited form as:

Int J Geriatr Psychiatry. 2024 April ; 39(4): e6086. doi:10.1002/gps.6086.

Marijuana use among community-dwelling older adults: A population-based study

Natacha M. De Genna^{1,2}, Erin Jacobsen³, Mary Ganguli^{2,4}

¹Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

²Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA

³Department of Psychiatry, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA

⁴Departments of Psychiatry and Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Abstract

Objectives: There is a paucity of population-level data on marijuana use and mental health and functioning in older adults.

Methods: We analyzed cross-sectional data ($n = 910$) from a well-characterized cohort, the Monongahela-Youghiogheny Healthy Aging Team (MYHAT) study. MYHAT is an age-stratified random sample of the population age 65 years and older from a small-town in the USA. Half the sample was female and half were over 75 (Mean age = 77). Most participants were non-Hispanic White. Marijuana use was assessed by self-report and symptoms of mood disorders were screened using the modified Centers for Epidemiological Studies-Depression Scale and the Generalized Anxiety Disorder screener. Cognition was assessed by the Mini-Mental State Examination and a neuropsychological test battery; functioning using the OARS Activities of Daily Living and Instrumental Activities of Daily Living; and overall assessment using the Clinical Dementia Rating (CDR[®]).

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Correspondence: Natacha M. De Genna, 3811 O'Hara St, Pittsburgh, PA 15213, USA. degennan@pitt.edu.

CONFLICT OF INTEREST STATEMENT

The authors have no conflicts of interest to disclose.

ETHICS STATEMENT

Ethical approval for this study was obtained from the University of Pittsburgh IRB.

PARTICIPANT CONSENT

All participants provided written informed consent prior to data collection.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

Results: One in five MYHAT participants had a history of marijuana use and 5% reported recent use, primarily for pain (41%) and recreation/relaxation (37%). Recent use was associated with cigarette and alcohol use, symptoms of depression or anxiety, and impairments in attention.

Conclusions: Twenty-percent of community-dwelling older adults living in a US state where recreational marijuana use is illegal had a history of marijuana use. Recent marijuana use was less common but, consistent with prior research, associated with other substance use and poorer mental health.

Keywords

anxiety; cannabis; depression; geriatric; marijuana; pain; substance use

1 | INTRODUCTION

Marijuana use among older adults has increased in higher income countries such as the USA,¹ Canada,^{2,3} and Australia,⁴ where the use of marijuana is either legal among adults (e.g., recreational marijuana laws) or physicians may prescribe it to treat specific medical conditions (medical marijuana laws). Data from medical marijuana prescriptions in the Netherlands show that 31% of medical marijuana patients in that country from 2003 to 2010 were between 61 and 80 years old.⁵ In the USA, the prevalence of past year marijuana use among individuals 65 years and older quadrupled between 2006 and 2018¹ and 74% of US citizens have access to either legal recreational marijuana or a medical marijuana prescription.⁶ Fewer older adults regard marijuana use a “great risk” to their health and wellbeing compared to previous decades.⁷ Although this may be partly due to US medical marijuana laws, the increase in marijuana use was greater among older adults with fewer chronic medical conditions.⁸ Thus, the increase in marijuana use among older US adults may not be simply due to medical marijuana used to treat chronic health conditions that are more common in this age group. In fact, older adults who use marijuana are not new initiates—most began using marijuana as adolescents.⁹ Nonetheless, the literature on marijuana use at the population level is limited for adults older than 65 years of age.

Correlates of marijuana use in older US adults include male sex, younger age, single marital status, non-Hispanic Black race and ethnicity, less than a college education, and combustible cigarette and other substance use.^{1,7,10–12} As is the case with over-the-counter supplements, there is a dearth of scientific evidence for the effectiveness of marijuana for medical conditions and few randomized clinical trials (RCTs) powered to examine adverse events in those 65 and older.^{13,14} In the absence of RCTs, the literature on marijuana use in older adults mainly consists of observational studies. More adverse effects of marijuana use are reported in RCTs than in observational studies.¹⁵ For example, older patients dosed with delta-9- tetrahydrocannabinol (THC) in a clinical trial were more likely to report dizziness or lightheadedness and thinking or perception disorder compared to patients on placebo or THC combined with cannabidiol (CBD).¹⁴ Similar symptoms (dizziness, lightheadedness, dry mouth) have been reported in older Canadian¹⁶ and Israeli¹⁷ adults using medicinal marijuana. In chart review studies, marijuana use among older patients has been associated with psychiatric, respiratory, cardiovascular, and neurologic conditions.^{18,19} Cross-sectional data from observational studies suggest that older people who use marijuana may have more

behavioral symptoms and reduced cognitive performance.^{20,21} Health care providers cannot turn to data from RCTs to inform patients about the risks and benefits of marijuana use, but observational data suggest that older people who use marijuana may have a higher risk profile than those who abstain.

In a constantly changing landscape with increasing legalization of marijuana and increased use in older people, more research is needed on marijuana use in people over 65 years of age, to better identify their health profiles. We tested associations between past-year marijuana use, health conditions, and cognitive functioning in a well-characterized population-based cohort of older adults in small-town communities in Pennsylvania, USA, where medical marijuana was legalized in 2016 and became widely available in 2018. As disparities in life expectancy continue to widen between urban and rural older adults,^{22,23} it is crucial to focus on health behaviors and outcomes in older adults from small towns and rural communities. Based on the prior literature on marijuana use in older adults, we hypothesized that participants with marijuana use would endorse more health conditions and worse cognitive functioning than participants without marijuana use, controlling for demographic factors and other substance use.

2 | MATERIALS AND METHODS

We analyzed data on marijuana use and functioning from the Monongahela-Youghiogheny Healthy Aging Team (MYHAT) study, a prospective cohort study of older adults residing in a group of small-town Rust-Belt communities in southwestern Pennsylvania (US). Participants are assessed annually for the development of mild cognitive impairment (MCI) and dementia, as described in detail elsewhere.^{24,25} Briefly, MYHAT is an age-stratified random sample of the population drawn from publicly available voter registration lists over two time periods, 2006–2008 and 2016–2019. Inclusion criteria were age 65 and older, residence in the targeted towns, not being in long-term care at study entry, hearing and vision sufficient to allow neuropsychological testing, and decisional capacity to provide informed consent. Identical procedures were used during the second recruitment period in 2016–2019, except that participants were restricted to age 65–74, thus replenishing the cohort with individuals who, during 2006–2008, were 10 years too young to be enrolled. All participants provided written informed consent, and all study procedures were approved by the University of Pittsburgh IRB.

2.1 | Participants

During the original recruitment period in 2006–2008, 2036 individuals aged 65p were enrolled into the MYHAT study, 1982 of whom underwent the full assessment after excluding 54 who already had substantial cognitive impairment as evidenced by age-education corrected scores of <21 on the Mini-Mental State Examination (MMSE).^{26,27} During the second recruitment period, 709 individuals enrolled, and 703 underwent the full study assessment. Medical marijuana became available in Pennsylvania in 2018, and in 2019, questions about participants' past and current use of marijuana were added to the study assessment. A total of 910 participants were administered the marijuana-related questions for the first time, which included individuals from both original and new cohorts at

different annual cycles. The assessment cycles at which each individual provided these data are treated as his/her study baseline for the current report, and other variables used here are also from that assessment cycle.

2.2 | Measures

2.2.1 | Predictor—Participants reported if they had ever used marijuana and if they answered affirmatively, if they had used marijuana in the past year. For the bivariate analysis, a trichotomous variable was used (0 = never used, 1 = former use only, 2 = past year use). For the multivariable association and sensitivity analyses, a dichotomous variable was created (0 = no current use, 1 = past year use). Participants with past year marijuana use were asked their reasons for use from a list of 12 options, including “other” and were able to endorse multiple options.

2.2.2 | Outcomes—Depression and Anxiety symptoms: Depressive symptoms were measured using the modified Center for Epidemiological Studies Depression scale (CES-D)²⁸ including all 20 original items but scoring each item as 0/1 (rather than 0–3) so that the maximum score was 20 (mCES-D).²⁹ Anxiety symptoms were measured with the Generalized Anxiety Disorder screener (GAD-7).³⁰

Symptoms of mood disorder: A dichotomous variable was created for symptoms of depression and anxiety using the 90th percentile of this study sample (1 = individuals who scored ≥ 4 on the mCES-D and/or ≥ 7 on the GAD-7).

Services for a mental disorder: Participants indicated whether a healthcare professional had told them that they had depression or anxiety and whether they had seen a mental health specialist in the past year.

Psychotropic medications: Participants reported all prescription medications they were currently using; we identified any psychotropic medication as an exposure for the current study.

Activities of Daily Living: Participants were rated on the Older Americans Resources and Services (OARS) Activities of Daily Living (ADL) and Instrumental ADL (IADL) scales.³¹

Cognitive screening: Participants were assessed on the MMSE as mentioned above. Impairment in this report was defined as being >1.5 SDs below their recruitment cohort’s mean.

Neuropsychological assessment: Participants were assessed with a cognitive test battery reported previously with test scores grouped into the cognitive domains of memory, language, executive function, attention/processing speed, and visuospatial ability. Standardized composite scores on each domain were identified as exposures.²⁵ Impairment was identified as scores being >1.5 SDs below their recruitment cohort’s mean.

Clinical Dementia Rating: Based on all available information excluding neuropsychological test performance, trained interviewers rated participants on the Clinical Dementia Rating

Staging Instrument (CDR[®]),³² which indicates impairment in cognitively driven everyday activity.

Subjective cognitive concerns: Participants responded to 21 questions regarding concerns about their own cognitive functioning.³³

Sleep quality: Participants were asked how often they had trouble falling asleep, had trouble going back to sleep if they awoke, waking up too early and not being able to go back to sleep, and falling asleep during the day while actively doing something. Response options for each sleep question ranged from 0 (never/rarely), 1 (sometimes), to 2 (usually). Responses of “sometimes” and “usually” were combined for the current study.

Pain: Participants reported whether they were experiencing any pain and rated the severity of their average pain and their worst pain in the past week on a scale of 1–10. Not all participants completed this measure.

Self-rated health: Participants rated their own health from 1 = poor to 5 = excellent. Categories were collapsed into poor/fair, good, and excellent/very good.

Self-reported hypertension: Participants were asked “Has a doctor or a nurse ever told you that you have high blood pressure (hypertension)?” At the baseline assessment, participants were asked if they were *ever* told; at follow-up visits, participants are asked if they were told *in the past year*.

2.2.3. | Covariates—Participants reported their age, sex, education, and marital status. Race was self-reported and categorized according to the US Census categories. Most of the participants identified as White (94%); some were Black (6%), more than one race (0.3%), Asian (0.1%), and American Indian/Alaskan Native (0.03%). Less than 1% identified as Hispanic. A dichotomous race variable was created for this analysis (NonWhite/White). Participants were also asked about their frequency of alcohol use and quantity of cigarette use in the past year. Dichotomous variables were created for these substances (weekly alcohol use and daily cigarette use).

2.3. | Statistical analysis

Bivariate analysis using chi-square tests were first conducted to examine the association between each covariate (demographic characteristics and other substance use) and marijuana use history (never, former, past year). Next, we examined bivariate associations between marijuana use history and the outcome variables using Chi-square tests or Fisher’s exact tests. Multivariable logistic regression analysis was used to determine if there were associations between recent marijuana use (any/none) and outcomes that were significant in the bivariate analysis. The adjusting covariates in all multivariable models included age, educational attainment, race, sex, daily tobacco use, and weekly alcohol use. Finally, sensitivity analyses were conducted to compare individuals with recent marijuana use to all others (never and past use) on demographic characteristics, substance use, and the health outcomes using Chi-square tests or Fisher’s exact test. Bivariate associations were

conducted using SAS software, version 9.4 (SAS Institute). Multivariable logistic regression models were fit using SPSS for Windows, version 28.0 (IBM).

3 | RESULTS

Half of the participants in this analysis were 65–75 years old and the other half were 76 years old or older (Table 1). One in five participants had previously used marijuana, and 5% reported use in the past year. As seen in Figure 1, most participants with recent marijuana use cited pain (41%) as the most common reason for use, followed closely by recreation/relaxation (37%), and social activity (22%).

In bivariate analysis, participants who reported recent (past year) marijuana use were more likely to be male, less than 75 years old, and more educated. They were also more likely to smoke combustible cigarettes and drink alcohol weekly, but there were no differences in race, marital status, or self-rated health, compared to participants without recent marijuana use (Table 1). Participants with past-year marijuana use were also more likely to report symptoms of anxiety, services for a mental disorder, recent pain, trouble falling back asleep and excessive daytime sleepiness (Table 1). Participants with past-year marijuana use were less likely to self-report hypertension and functional impairment in ADLs and IADLs (Table 1).

In the multivariable logistic regression models, adjusting for demographics and current alcohol and tobacco use, past year marijuana use was significantly associated with concurrent anxiety or depression symptoms (Table 2: adjusted Odds Ratio [aOR] = 2.36 [95% CI: 1.19–4.69]), attention impairment (aOR = 2.92 [95% CI: 1.02–8.35]), and problems falling back asleep if awakened at night (aOR = 2.46 [95% CI: 1.34–4.52]). After adjustment, past year marijuana use was not associated with IADL and ADL scales, hypertension, or daytime sleepiness.

In the sensitivity analysis, participants who had used marijuana in the past year were more likely to be younger and more educated and reported more cigarette and alcohol use than those without recent marijuana use. However, there was no sex difference between those with recent use and those who had never used or had no past year marijuana use (Supplementary Table S1). As with the main analysis, participants with past year marijuana use had more symptoms of anxiety on the GAD-7 screener, were more likely to have had a health care provider diagnose them with depression or anxiety or received services for a mental disorder, pain, and trouble going back to sleep when awakened, and were less likely to have hypertension compared to all others. However, there were no differences in daytime sleepiness or activities of daily living (Supplementary Table S1).

4 | DISCUSSION

In this population-based study of adults over age 65 from a small-town under-resourced community in the USA, one in five participants reported a history of marijuana use, and one in 20 had used marijuana in the past year. Rates of marijuana use among older adults may be even higher among medical marijuana users^{5,34} and those living in regions that have legalized recreational marijuana use.^{16,35–37} Pain was the most cited reason for marijuana

use in our sample, consistent with other studies of community-dwelling older adults.^{16,17,36} Findings are mixed with regards to effective pain relief among medical marijuana patients, with improvements reported in Canadian¹⁶ and Israeli¹⁷ samples, but no differences in symptom scores for pain, nausea, appetite, insomnia, or anxiety scores measured before and after patients initiated medical marijuana use in a chart review study of US cancer patients over 65 years.³⁸ Of note, two-thirds of participants with recent marijuana use in this study reported recreational reasons for use including recreation/relaxation, social activity, boredom, habit, and creativity/music/art appreciation. This may be a cohort effect, as 81% of them were “Baby Boomers,” a cohort of individuals in the USA characterized by increasing acceptance and use of marijuana. Thus, this study contributes to a small but growing literature on marijuana use in adults over the age of 65, highlighting the prevalence and correlates of use in older people from small towns who use marijuana for pain as well as non-medical reasons.

Healthcare providers in regions without legal recreational marijuana, such as Pennsylvania, should be aware that some of their older patients may be using marijuana for recreational purposes. Participants in this study who had recently used marijuana were more likely to suffer from attention impairment and sleep problems despite being younger, on average, than individuals without recent marijuana use. In addition, bivariate analysis conducted on a subsample of participants with pain data revealed that individuals with past year marijuana use reported greater average pain and more severe pain in the past week than those without recent marijuana use. It may therefore be useful for clinicians to ask older patients with pain and sleep continuity problems whether they are using marijuana. Older people who use marijuana also tend to use combustible cigarettes and alcohol¹² and thus represent a higher-risk population. Participants with recent marijuana use did not rate their health more poorly than those without recent marijuana use. This is consistent with prior research suggesting that, unlike people under the age of 65,³⁹ marijuana use is less common among older individuals who suffer from multiple chronic health conditions than those without such conditions.⁸

Although past year marijuana use was linked to subjective memory complaints in a recent population-level analysis of US adults over 50,⁴⁰ past year marijuana use was not associated with subjective memory complaints or memory test scores in our study with individuals over 65. A pilot study of brain structure in older adults using MRI scans found no differences between individuals who were current marijuana users compared to those who were non-users⁴¹ but there may be functional differences, as reflected in reduced cognitive performance in older adults with a history of heavier or more frequent marijuana use.²⁰ A review of PET studies on molecular brain differences found evidence for a link between marijuana use and striatum dopamine synthesis capacity, and this was related to inattention, working memory deficits, negative mood, and cravings among individuals with marijuana use or Cannabis Use Disorder.⁴² In one small (n = 16) crossover RCT of US patients with diabetic peripheral neuropathy, those who inhaled a high dose of vaporized marijuana leaf reported an analgesic effect but also experienced reductions in attention/working memory that might have an impact on daily activities such as driving.⁴³ Health care providers can caution their marijuana-using patients to avoid “driving while high.” Future research in larger samples of older adults may have sufficient numbers of participants with current

marijuana use to allow results to be stratified by amount and frequency of use and/or by type or dose of marijuana.

Our study participants with recent marijuana use also reported more psychiatric distress, including symptoms of anxiety, compared to participants without recent marijuana use. Individuals who had used marijuana in the past year were twice as likely as non-users to report services for a mental disorder, including depression and anxiety, in the past year. One-third of participants with recent marijuana use had been prescribed a psychotropic medication, compared to a quarter of those with no history or no recent use of marijuana. These findings are consistent with prior studies linking marijuana use to mental health problems in older adults.^{15,21,43} Although some individuals with mood disorders may be attempting to self-medicate their symptoms with marijuana, there is evidence from longitudinal studies of younger people that marijuana use, especially frequent and/or heavy use, increases the likelihood of these symptoms.^{44–48} Similarly, reductions in marijuana use may result in decreased depression scores^{49,50} although this work needs to be replicated in older adults. Research conducted in younger people indicates that the link between marijuana use and psychiatric symptoms may be related to reduced dopamine synthesis capacity in individuals who use marijuana.⁴¹ People who are aging outside of bigger cities are more likely to rely on general practitioners to assess for mental health and less likely to access specialty care than people living in urban areas, even with the growth of telehealth services.⁵¹ The results of this study suggest that primary care providers should assess for mental health problems in older patients who use marijuana.

Although this was a large US sample of community-dwelling adults aged 65 and older with robust measures of mental health and standardized assessments of cognitive functioning, there are some limitations to consider. These data are cross-sectional and therefore provide no information about directionality or causality. More longitudinal research of adults followed into late adulthood is needed to determine if years and quantity of marijuana use have an impact on pain or cognitive decline in those without prior history of these conditions. The results of this study also may not generalize to other populations of older adults who live in rural or large urban areas, different racial and ethnic groups, and from other countries. For example, the small-town largely White population sampled for this study were not the target of the “War on Drugs” that penalized marijuana use disproportionately among Black and indigenous people in North America, amplifying health inequities for these communities.^{52,53} More focus is needed on the implications of marijuana use among older people from racial and ethnic minority groups and more research is needed on marijuana use in older adults from lower and middle income (LMIC) countries.⁵⁴ Marijuana use is more common in urban areas^{55,56} so this analysis may underestimate use among older adults. It is possible that older adults from small towns who use marijuana may represent people who are at greater risk of health behaviors than older people from large urban areas. However, the prevalence of recent marijuana use in this sample was consistent with what has been reported in national US samples with similar demographic correlates of use.⁸ Another limitation was that pain in the past week was only measured in a small subset of the participants, and thus multivariate results were not conducted on average pain or most severe pain in the past week. Longitudinal studies with repeated measures of pain are needed

to determine if marijuana use is associated with alleviation of different types of pain in older adults.

4.1 | Conclusion

As medical and recreational marijuana use becomes available more widely, more older individuals are likely to use marijuana^{4,8} and may need advice from healthcare providers regarding marijuana use. Marijuana use has not only been linked to poorer mental health among older populations but may also interact with prescription drugs commonly used in this population such as warfarin.⁵⁷ Older people who use marijuana may also be at greater risk of motor vehicle accidents⁵⁸ and other marijuana-related problems compared to younger adults.⁵⁹ Health care providers should consider routinely asking all their patients, regardless of their age, about marijuana use in the same non-judgmental manner they ask about use of herbal supplements, tobacco, and alcohol. As with alcohol and tobacco use, discussions about the possible harms of marijuana use and suggestions for harm reduction should be part of discussions with providers. Patients who use marijuana for medical reasons should be offered more effective, evidence-based treatment for those conditions. Some older people in medical marijuana states may be pleased to have access to marijuana as another treatment option, but frustrated that science and therefore their physicians, currently cannot provide accurate information about dosing and adverse effects.⁶⁰

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

The authors thank Dr. Chung-Chou H. Chang for valuable comments, all the MYHAT personnel, and all MYHAT participants for their time and efforts. This study was funded by the National Institute on Aging (R37AG023651). The NIA was not involved in the design, methods, subject recruitment, data collection, analysis or preparation of the paper.

Funding information

National Institute of Aging, Grant/Award Number: R37AG023651

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

1. Han BH, Palamar JJ. Marijuana use by middle-aged and older adults in the United States, 2015–2016. *Drug Alcohol Depend.* 2018;191: 374–381. 10.1016/j.drugalcdep.2018.07.006 [PubMed: 30197051]
2. Rotermann M Looking back from 2020, how cannabis use and related behaviours changed in Canada. *Health Rep* 2021;32:3–14. 10.25318/82-003-x202100400001-eng
3. Wadsworth E, Cristiano N, Gabrys R, Renard J, Hammond D. Cannabis consumption among adults aged 55–65 in Canada, 2018–2021. *J Drug Issues.* 2023:00220426231190022. 10.1177/00220426231190022

4. Kaur N, Keyes KM, Hamilton AD, et al. Trends in cannabis use and attitudes toward legalization and use among Australians from 2001–2016: an age-period-cohort analysis. *Addiction*. 2021;116(5): 1152–1161. 10.1111/add.15271 [PubMed: 32949418]
5. Hazekamp A, Heerdink ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. *Eur J Clin Pharmacol* 2013;69(8):1575–1580. 10.1007/s00228-013-1503-y [PubMed: 23588562]
6. Chapekis A, Shaw S. Most Americans Now Live in a Legal Marijuana State – and Most Have at Least One Dispensary in Their County. Pew Research Center; 2024. Accessed at on March 25, 2024. <https://www.pewresearch.org/short-reads/2024/02/29/most-americans-now-live-in-a-legal-marijuana-state-and-most-have-at-least-one-dispensary-in-their-county/>
7. Salas-Wright CP, Vaughn MG, Cummings-Vaughn LA, et al. Trends and correlates of marijuana use among late middle-aged and older adults in the United States, 2002–2014. *Drug Alcohol Depend*. 2017;171:97–106. 10.1016/j.drugalcdep.2016.11.031 [PubMed: 28063338]
8. Han BH, Palamar JJ. Trends in cannabis use among older adults in the United States, 2015–2018. *JAMA Intern Med* 2020;180(4):609–611. 10.1001/jamainternmed.2019.7517 [PubMed: 32091531]
9. Choi NG, DiNitto DM, Marti CN. Older-adult marijuana users and ex- users: comparisons of sociodemographic characteristics and mental and substance use disorders. *Drug Alcohol Depend*. 2016;165:94–102. 10.1016/j.drugalcdep.2016.05.023 [PubMed: 27282425]
10. DiNitto DM, Choi NG. Marijuana use among older adults in the USA: user characteristics, patterns of use, and implications for intervention. *Int Psychogeriatr* 2011;23(5):732–741. 10.1017/S1041610210002176 [PubMed: 21108863]
11. Han BH, Sherman S, Mauro PM, Martins SS, Rotenberg J, Palamar JJ. Demographic trends among older cannabis users in the United States, 2006–13. *Addiction*. 2017;112(3):516–525. 10.1111/add.13670 [PubMed: 27767235]
12. Kepner WE, Han BH, Nguyen D, Han SS, Lopez FA, Palamar JJ. Past- month binge drinking and cannabis use among middle-aged and older adults in the United States, 2015–2019. *Alcohol*. 2023;107: 32–37. 10.1016/j.alcohol.2022.07.006 [PubMed: 35934163]
13. Fick DM. Evaluating the safety of cannabinoid-based medicines for older adults. *JAMA Netw Open*. 2021;4(2):e2035952. 10.1001/jamanetworkopen.2020.35952 [PubMed: 33528548]
14. Velayudhan L, McGoochan KL, Bhattacharyya S. Evaluation of THC- related neuropsychiatric symptoms among adults aged 50 years and older: a systematic review and metaregression analysis. *JAMA Netw Open*. 2021;4(2):e2035913. 10.1001/jamanetworkopen.2020.35913 [PubMed: 33528550]
15. Wolfe D, Corace K, Butler C, et al. Impacts of medical and non- medical cannabis on the health of older adults: findings from a scoping review of the literature. *PLoS One*. 2023;18(2):e0281826. 10.1371/journal.pone.0281826 [PubMed: 36800328]
16. Tumati S, Lanctôt KL, Wang R, Li A, Davis A, Herrmann N. Medical cannabis use among older adults in Canada: self-reported data on types and amount used, and perceived effects. *Drugs Aging*. 2022;39(2):153–163. 10.1007/s40266-021-00913-y [PubMed: 34940961]
17. Abuhasira R, Schleider LBL, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. *Eur J Intern Med* 2018;49:44–50. 10.1016/j.ejim.2018.01.019 [PubMed: 29398248]
18. Asmar S, Nelson A, Anand T, et al. Marijuana and thromboembolic events in geriatric trauma patients: the cannabinoids clots correlation. *Am J Surg* 2022;223(4):798–803. 10.1016/j.amjsurg.2021.07.036 [PubMed: 34334193]
19. Javanbakht M, Takada S, Akabike W, Shoptaw S, Gelberg L. Cannabis use, comorbidities, and prescription medication use among older adults in a large healthcare system in Los Angeles, CA 2019–2020. *J Am Geriatr Soc* 2022;70(6):1673–1684. 10.1111/jgs.17719 [PubMed: 35234291]
20. Scott EP, Brennan E, Benitez A. A systematic review of the neurocognitive effects of cannabis use in older adults. *Curr Addict Rep* 2019;6(4):443–455. 10.1007/s40429-019-00285-9 [PubMed: 32477850]
21. Vacaflor BE, Beauchet O, Jarvis GE, Schavietto A, Rej S. Mental health and cognition in older cannabis users: a review. *Can Geriatr J* 2020;23(3):242–249. 10.5770/cgj.23.399 [PubMed: 32904776]

22. Cosby AG, McDoom-Echebiri MM, James W, Khandekar H, Brown W, Hanna HL. Growth and persistence of place-based mortality in the United States: the rural mortality penalty. *Am J Publ Health*. 2019;109(1):155–162. 10.2105/AJPH.2018.304787
23. Singh GK, Siahpush M. Widening rural–urban disparities in life expectancy, US, 1969–2009. *Am J Prev Med* 2014;46(2):e19–e29. 10.1016/j.amepre.2013.10.017 [PubMed: 24439358]
24. Ganguli M, Snitz B, Bilt JV, Chang CH. How much do depressive symptoms affect cognition at the population level? The Monongahela–Youghiogheny Healthy Aging Team (MYHAT) study. *Int J Geriatr Psychiatr* 2009;24(11):1277–1284. 10.1002/gps.2257
25. Ganguli M, Snitz BE, Lee CW, Vanderbilt J, Saxton JA, Chang CCH. Age and education effects and norms on a cognitive test battery from a population-based cohort: the Monongahela–Youghiogheny Healthy Aging Team. *Aging Ment Health*. 2010;14(1):100–107. 10.1080/13607860903071014 [PubMed: 20155526]
26. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;12(3):189–198. 10.1016/0022-3956(75)90026-6 [PubMed: 1202204]
27. Mungas D, Marshall SC, Weldon M, Haan M, Reed BR. Age and education correction of mini-mental state examination for English and Spanish-speaking elderly. *Neurology*. 1996;46(3):700–706. 10.1212/wnl.46.3.700 [PubMed: 8618670]
28. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. *Appl Psychol Meas* 1977;1(3): 385–401. 10.1177/014662167700100306
29. Ganguli M, Gilby J, Seaberg E, Belle S. Depressive symptoms and associated factors in a rural elderly population: the MoVIES project. *Am J Geriatr Psychiatr* 1995;3(2):144–160. 10.1097/00019442-199500320-00006
30. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166(10):1092–1097. 10.1001/archinte.166.10.1092 [PubMed: 16717171]
31. Fillenbaum GG. Multidimensional Functional Assessment of Older Adults: The Duke Older Americans Resources and Services Procedures. Lawrence Erlbaum Associates, Inc; 1988.
32. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43(11):2412–2414. 10.1212/wnl.43.11.2412-a
33. Snitz BE, Yu L, Crane P, Chang CH, Hughes TF, Ganguli M. Subjective cognitive complaints of older adults at the population level: an item response theory analysis. *Alzheimer Dis Assoc Disord* 2012;26(4): 344–351. 10.1097/WAD.0b013e3182420bdf [PubMed: 22193355]
34. Kaufmann CN, Kim A, Miyoshi M, Han BH. Patterns of medical cannabis use among older adults from a cannabis dispensary in New York state. *Cannabis and Cannabinoid Res* 2022;7(2):224–230. 10.1089/can.2020.0064 [PubMed: 33998868]
35. National Cannabis Survey. Component of Statistics Canada Catalogue (Online); 2019. Available at. Accessed 30 June 2023. https://www150.statcan.gc.ca/n1/en/daily-quotidien/190502/dq190502a-eng.pdf?st=NAG_XCni
36. Reynolds IR, Fixen DR, Parnes BL, et al. . Characteristics and patterns of marijuana use in community-dwelling older adults. *J Am Geriatr Soc* 2018;66(11):2167–2171. 10.1111/jgs.15507 [PubMed: 30291748]
37. Yang KH, Kaufmann CN, Nafsu R, et al. Cannabis: an emerging treatment for common symptoms in older adults. *J Am Geriatr Soc* 2021;69(1):91–97. 10.1111/jgs.16833 [PubMed: 33026117]
38. Nathan R, Mupamombe CT, Elibol J, et al. Assessing efficacy and use patterns of medical cannabis for symptom management in elderly cancer patients. *Am J Hosp Palliat Care*. 2023;40(4):368–373. 10.1177/10499091221110217 [PubMed: 35749740]
39. Dai H, Richter KP. A national survey of marijuana use among US adults with medical conditions, 2016–2017. *JAMA Netw Open*. 2019;2(9):e1911936. 10.1001/jamanetworkopen.2019.11936 [PubMed: 31539078]
40. Mulhauser K, Hampstead BM, Coughlin LN, Ilgen MA. The association between cannabis use and subjective memory complaints in older adults in the United States. *J Int Neuropsychol Soc* 2023;29(9):870–877. 10.1017/S1355617723000061 [PubMed: 36803905]

41. Thayer RE, York Williams SL, Hutchison KE, Bryan AD. Preliminary results from a pilot study examining brain structure in older adult cannabis users and nonusers. *Psychiatric Res: Neuroimaging*. 2019;285:58–63. 10.1016/j.psychresns.2019.02.001 [PubMed: 30785022]
42. Xu H, Owens MM, Farncombe T, Noseworthy M, MacKillop J. Molecular brain differences and cannabis involvement: a systematic review of positron emission tomography studies. *J Psychiatr Res* 2023;162:44–56. 10.1016/j.jpsychires.2023.03.045 [PubMed: 37088043]
43. Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. *J Pain* 2015;6(7):616–627. 10.1016/j.jpain.2015.03.008
44. Bahorik AL, Leibowitz A, Sterling SA, Travis A, Weisner C, Satre DD. Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. *J Affect Disord* 2017;213:168–171. 10.1016/j.jad.2017.02.016 [PubMed: 28242498]
45. Davis JP, Pedersen ER, Tucker JS, et al. Directional associations between cannabis use and depression from late adolescence through young adulthood: the role of adverse childhood experiences. *Addiction*. 2023;118(6):1083–1092. 10.1111/add.16130 [PubMed: 36648021]
46. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. *Addiction*. 2003;98(11):1493–1504. 10.1046/j.1360-0443.2003.00437.x [PubMed: 14616175]
47. Gobbi G, Atkin T, Zytynski T, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. *JAMA Psychiatr* 2019;76(4):426–434. 10.1001/jamapsychiatry.2018.4500
48. Smolkina M, Morley KI, Rijdsdijk F, et al. Cannabis and depression: a twin model approach to comorbidity. *Behav Genet* 2017;47(4): 394–404. 10.1007/s10519-017-9848-0 [PubMed: 28466235]
49. Hser YI, Mooney LJ, Huang D, et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. *J Subst Abuse Treat*. 2017;81:53–58. 10.1016/j.jsat.2017.07.012 [PubMed: 28847455]
50. Moitra E, Anderson BJ, Stein MD. Reductions in cannabis use are associated with mood improvement in female emerging adults. *Depress Anxiety*. 2016;33(4):332–338. 10.1002/da.22460 [PubMed: 26636547]
51. Patel SY, Huskamp HA, Busch AB, Mehrotra A. Telemental health and US rural-urban differences in specialty mental health use, 2010–2017. *Am J Publ Health*. 2020;110(9):1308–1314. 10.2105/AJPH.2020.305657
52. Cohen A, Vakharia SP, Netherland J, Frederique K. How the war on drugs impacts social determinants of health beyond the criminal legal system. *Ann Med* 2022;54(1):2024–2038. 10.1080/07853890.2022.2100926 [PubMed: 35852299]
53. Owusu-Bempah A, Luscombe A. Race, cannabis and the Canadian war on drugs: an examination of cannabis arrest data by race in five cities. *Int J Drug Pol* 2021;91:102937. 10.1016/j.drugpo.2020.102937
54. Ransing R, de la Rosa PA, Pereira-Sanchez V, et al. Current state of cannabis use, policies, and research across sixteen countries: cross-country comparisons and international perspectives. *Trends Psychiatry Psychother* 2022;44:e20210263. 10.47626/2237-6089-2021-0263 [PubMed: 34735077]
55. Coughlin LN, Bonar EE, Bohnert KM, et al. Changes in urban and rural cigarette smoking and cannabis use from 2007 to 2017 in adults in the United States. *Drug Alcohol Depend*. 2019;205:107699. 10.1016/j.drugalcdep.2019.107699 [PubMed: 31707265]
56. Moore JR, Chen Q, Choi NG. Cannabis use, use frequency, and use disorder in large metropolitan, small metropolitan, and nonmetropolitan areas. *Drug Alcohol Depend*. 2021;221:108631. 10.1016/j.drugalcdep.2021.108631 [PubMed: 33647587]
57. Antoniou T, Bodkin J, Ho JM. Drug interactions with cannabinoids. *Can Med Assoc J* 2020;192(9):E206. 10.1503/cmaj.191097 [PubMed: 32122975]
58. Davis S, Betz ME, Hill LL, et al. Associations of cannabis use with motor vehicle crashes and traffic stops among older drivers: AAA LongROAD study. *Traffic Inj Prev* 2023;24(4):307–314. 10.1080/15389588.2023.2180736 [PubMed: 36939676]

59. Imtiaz S, Nigatu YT, Ali F, et al. Cannabis legalization and cannabis use, daily cannabis use and cannabis-related problems among adults in Ontario, Canada (2001–2019). *Drug Alcohol Depend.* 2023;244: 109765. 10.1016/j.drugalcdep.2023.109765 [PubMed: 36652851]
60. Manning L, Bouchard L. Medical cannabis use: exploring the perceptions and experiences of older adults with chronic conditions. *Clin Gerontol* 2021;44(1):32–41. 10.1080/07317115.2020.1853299 [PubMed: 33250007]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Key points

- One in five adults over 65 who live in a state without legal recreational marijuana laws have a history of marijuana use.
- Adults over 65 with recent marijuana use are more likely to smoke cigarettes and drink alcohol.
- Adults over 65 use marijuana for pain relief and recreation/relaxation.
- As with younger adults, recent marijuana use in people over 65 is associated with symptoms of depression and anxiety.




FIGURE 1.
Reasons for recent marijuana among community-dwelling adults over 65 with past-year use
(*n* = 48).

Table 1

Sample characteristics and health problems as a function of marijuana use history.

Total N = 910								Never used marijuana N = 679	Former use marijuana N = 183	Recent use (past year) N = 48	p value ^a
N (col %)											
Covariates											
Sex	Female	572 (62.9)	460 (67.8)	87 (47.5)	25 (52.1)	<0.0001					
	Male	338 (37.1)	219 (32.3)	96 (52.5)	23 (47.9)						
Race	Black, Asian, AIAN	63 (6.9)	41 (6.0)	18 (9.8)	4 (8.3)	0.184					
	White	847 (93.1)	638 (94.0)	165 (90.2)	44 (91.7)						
Education	< High school	29 (3.2)	28 (4.1)	0	1 (3.5)	<0.0001					
	High school	309 (34.0)	262 (38.6)	39 (21.3)	8 (16.7)						
Age	> High school	572 (62.9)	389 (57.3)	144 (78.7)	39 (81.3)						
	65–74 years	452 (49.7)	259 (38.1)	152 (83.1)	41 (85.4)	<0.0001					
	75–84 years	279 (30.7)	244 (35.9)	28 (15.3)	7 (14.6)						
	85+ years	179 (19.7)	176 (25.9)	3 (1.6)	0 (0)						
Married/living as married	Yes	418 (47.6)	310 (47.2)	88 (49.7)	20 (44.4)	0.762					
	Unmarried	461 (52.5)	347 (52.8)	89 (50.3)	25 (55.6)						
Weekly alcohol use	No	738 (81.3)	568 (83.8)	140 (76.5)	30 (63.8)	0.001					
	Yes	170 (18.7)	110 (16.2)	43 (23.5)	17 (36.2)						
Current cigarette use	No	850 (93.4)	649 (95.6)	161 (88.0)	40 (83.3)	<0.0001					
	Yes	60 (6.6)	30 (4.4)	22 (12.0)	8 (16.7)						
Outcomes											
Self-rated health	Excellent/very good	390 (42.9)	285 (42.0)	83 (45.4)	22 (45.8)	0.868					
	Good	389 (42.8)	292 (43.0)	77 (42.1)	20 (41.7)						
Depression (mCES-D) ^b	Poor/fair	131 (14.4)	102 (15.0)	23 (12.6)	6 (12.5)						
	3	785 (87.2)	587 (87.5)	159 (87.9)	39 (81.3)	0.441					
Anxiety (GAD7) ^c	4	115 (12.8)	84 (12.5)	22 (12.2)	9 (18.8)						
	6	806 (89.5)	604 (89.9)	165 (91.2)	37 (77.1)	0.014					
Services for a mental disorder	7	95 (10.5)	68 (10.1)	16 (8.8)	11 (22.9)						
	No	674 (76.5)	515 (78.3)	133 (74.7)	26 (57.8)	0.006					
	Yes	207 (23.5)	143 (21.7)	45 (25.3)	19 (42.2)						

Total N = 910												Never used marijuana N = 679		Former use marijuana N = 183		Recent use (past year) N = 48		p value
N (col %)																		
Psychotropic Rx drug use	No	650 (74.2)										490 (74.8)		131 (74.0)		29 (65.9)		0.425
	Yes	226 (25.8)										165 (25.2)		46 (26.0)		15 (34.1)		
CDR	0	721 (82.1)										528 (80.4)		157 (88.7)		36 (81.8)		0.094
	0.5	138 (15.7)										112 (17.1)		19 (10.7)		7 (15.9)		
MMSE impairment	1	19 (2.2)										17 (2.6)		1 (0.6)		1 (2.3)		
	No	742 (90.1)										555 (89.9)		150 (93.2)		37 (92.5)		0.264
Attention impairment	Yes	82 (10.0)										68 (10.9)		11 (6.8)		3 (7.5)		
	No	828 (93.2)										613 (92.9)		172 (95.6)		43 (89.6)		0.261
Executive function impairment	Yes	60 (6.8)										47 (7.1)		8 (4.4)		5 (10.4)		
	No	832 (92.1)										623 (92.7)		167 (91.3)		42 (87.5)		0.382
Language impairment	iYes	71 (7.9)										49 (7.3)		16 (8.7)		6 (12.5)		
	No	822 (92.5)										609 (92.3)		169 (93.4)		44 (91.7)		0.864
Memory impairment	Yes	67 (7.5)										51 (7.7)		12 (6.6)		4 (8.3)		
	No	815 (93.0)										606 (93.7)		167 (92.3)		42 (87.5)		0.243
Visuospatial impairment	Yes	61 (7.0)										41 (6.3)		14 (7.7)		6 (12.5)		
	No	613 (93.5)										431 (92.7)		146 (95.4)		36 (94.7)		0.468
IADL score ^d	Yes	43 (6.6)										34 (7.3)		7 (4.6)		2 (5.3)		
	0	670 (76.7)										476 (72.9)		157 (88.7)		37 (84.1)		<0.0001
ADL score ^e	1	204 (23.3)										177 (27.1)		20 (11.3)		7 (15.9)		
	0	641 (73.0)										451 (68.7)		153 (86.4)		37 (84.1)		<0.0001
Subjective memory complaints ^f	1	237 (27.0)										206 (31.4)		24 (13.6)		7 (15.9)		
	0-2	591 (65.0)										434 (63.9)		125 (68.3)		32 (66.7)		0.5442
Self-report hypertension	3-5	223 (24.5)										171 (25.2)		43 (23.5)		9 (18.8)		
	6	96 (10.6)										74 (10.9)		15 (8.2)		7 (14.6)		
Worst pain severity N = 85	No	323 (35.5)										223 (32.8)		76 (41.5)		24 (50.0)		0.009
	Yes	587 (64.5)										456 (67.2)		107 (58.5)		24 (50.0)		
Average pain severity N = 84	No pain past week	46 (54.1)										26 (47.3)		19 (86.4)		1 (12.5)		0.001
	1-7	23 (27.1)										19 (34.6)		1 (4.6)		3 (37.5)		
	8	16 (18.8)										10 (18.2)		2 (9.1)		4 (50.0)		
	No pain past week	46 (54.8)										26 (48.2)		19 (86.4)		1 (12.5)		0.002

Total N = 910		Never used marijuana N = 679	Former use marijuana N = 183	Recent use (past year) N = 48	p value ^a
N (col %)					
Trouble falling asleep	1–4	15 (17.9)	11 (20.4)	1 (4.6)	3 (37.5)
	5	23 (27.4)	17 (31.5)	2 (9.1)	4 (50.0)
	Never/rarely	627 (68.9)	467 (68.8)	131 (71.6)	29 (60.4)
	Sometimes/usually	283 (31.1)	212 (31.2)	52 (28.4)	19 (39.6)
	Never/rarely	580 (63.7)	433 (63.8)	124 (67.8)	23 (47.9)
Trouble going back to sleep if awakened					0.039
	Sometimes/usually	330 (36.3)	246 (36.2)	59 (32.2)	25 (52.1)
Wake earlier than want	Never/rarely	622 (68.4)	469 (69.1)	126 (68.9)	27 (56.3)
	Sometimes/usually	288 (31.7)	210 (30.9)	57 (31.2)	21 (43.8)
Excessive daytime sleepiness	Never/rarely	466 (51.2)	333 (49.0)	110 (60.1)	23 (47.9)
	Sometimes/usually	444 (48.8)	346 (51.0)	73 (39.9)	25 (52.1)

Abbreviations: ADL, activities of daily living; AIAN, American Indian/Alaskan Native; CDR, Clinical Dementia Rating; GAD7, Generalized Anxiety Disorder 7-item assessment; IADL, independent activities of daily living; mCES-D, modified Center for Epidemiological Studies Depression scale; MMSE, Mini-Mental State Examination.

^a Chi-square tests and Fisher's exact tests were used to test associations.

^b mCES-D score range 0–20.

^c GAD7 score range 0–21.

^d IADL score range 0 (independent) to 7.

^e ADL score range 0 (independent) to 6.

^f subjective memory complaints score range 0–21.

Table 2

Adjusted odds ratios of recent marijuana use^a.

Outcome variable	Odds ratio (OR)	95% confidence interval	Wald test statistic
Depression/Anxiety	2.36	1.19–4.69	6.04**
Attention impairment	2.92	1.02–8.35	4.00*
Problems falling back asleep	2.46	1.34–4.52	8.36**

^a 0 = no current use, 1 = past year use; adjusting for daily cigarette use, weekly alcohol use, education attainment, age, race, and sex.

* = $p < 0.05$

** = $p < 0.01$

*** = $p < 0.001$.